Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
Type:
Application
Filed:
October 30, 2007
Publication date:
April 28, 2011
Applicant:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.
Type:
Application
Filed:
October 6, 2009
Publication date:
April 22, 2010
Applicants:
GENIMMUNE, PHARMEXA INC.
Inventors:
Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert W. Chesnut, Mark Newman, Alessandra Sette, John Sidney, Scott Southwood
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
Type:
Application
Filed:
August 5, 2009
Publication date:
March 18, 2010
Applicant:
Pharmexa Inc.
Inventors:
Alessandro SETTE, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
Type:
Application
Filed:
October 30, 2007
Publication date:
December 17, 2009
Applicant:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
Type:
Grant
Filed:
September 4, 2003
Date of Patent:
November 3, 2009
Assignee:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Type:
Grant
Filed:
December 11, 2000
Date of Patent:
August 11, 2009
Assignee:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Howard M. Grey
Abstract: The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity.
Type:
Grant
Filed:
June 27, 2001
Date of Patent:
December 9, 2008
Assignee:
Pharmexa Inc.
Inventors:
Alessandro Sette, Robert Chesnut, Brian D. Livingston, Denise Marie Baker, Mark J. Newman
Abstract: A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.
Type:
Grant
Filed:
May 4, 1993
Date of Patent:
April 29, 2008
Assignee:
Pharmexa Inc.
Inventors:
Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette, John C. Sidney
Abstract: The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.
Type:
Application
Filed:
May 18, 2007
Publication date:
February 7, 2008
Applicant:
Pharmexa Inc.
Inventors:
Jeffery Alexander, Pamuk Bilsel, Mark Newman
Abstract: The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.
Type:
Grant
Filed:
November 8, 2000
Date of Patent:
April 10, 2007
Assignee:
Pharmexa Inc.
Inventors:
Alessandro Sette, Federico Gaeta, Howard M. Grey, John Sidney, Jeffery L. Alexander
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
Type:
Application
Filed:
September 18, 2006
Publication date:
March 15, 2007
Applicant:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut